Education
About Us
Working with TipRanks
Follow Us
ARS Pharmaceuticals (SPRY)
NASDAQ:SPRY
SPRY Stock Chart & Stats
$9.56
-$0.02(-0.18%)
At close: 4:00 PM EST
$9.56
-$0.02(-0.18%)
Day’s Range― - ―
52-Week Range$9.08 - $18.90
Previous CloseN/A
Volume456.05K
Average Volume (3M)2.43M
Market Cap
$900.31M
Enterprise Value$1.48B
Total Cash (Recent Filing)$240.13M
Total Debt (Recent Filing)$1.66M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Nov 06, 2025EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding98,826,340
10 Day Avg. Volume1,705,398
30 Day Avg. Volume2,431,432
Financial Highlights & Ratios
PEG Ratio-1.12
Price to Book (P/B)3.98
Price to Sales (P/S)11.47
P/FCF Ratio78.76
Enterprise Value/Market Cap1.64
Enterprise Value/Revenue13.16
Enterprise Value/Gross Profit14.04
Enterprise Value/Ebitda-27.04
Forecast
1Y Price Target
$31.00Price Target Upside224.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe publication shares real-world evidence evaluating the performance of neffy in 545 patients experiencing anaphylaxis symptoms during oral food allergy challenge and allergen immunotherapy.
Market ExpansionNeffy approval in Japan expands the geographic reach of the product, which is already available in the U.S. and Germany and has recently received approval in the U.K.
Marketing InvestmentThe company highlighted potential to invest in marketing and medical affairs initiatives to disseminate and raise awareness of the growing body of literature showing that neffy’s real-world effectiveness is consistent with that of traditional epinephrine injections.
Bears Say
Healthcare Provider ChallengesManagement noted that it had underappreciated how overwhelmed by patient volumes practices would be during these peak weeks, which makes doctors less willing to prescribe a new treatment.
Prescription TrendsEnding the GoodRx program has been a headwind for weekly script numbers that have underwhelmed investors in recent weeks; however, this should have minimal impact on revenue.
Stock PerformanceThe weakness in shares of ARS in recent weeks, down over 40% since its highs in July, is considered unwarranted despite facing some headwinds.
ARS Pharmaceuticals News
SPRY FAQ
What was ARS Pharmaceuticals’s price range in the past 12 months?
ARS Pharmaceuticals lowest stock price was $9.08 and its highest was $18.90 in the past 12 months.
What is ARS Pharmaceuticals’s market cap?
ARS Pharmaceuticals’s market cap is $900.31M.
When is ARS Pharmaceuticals’s upcoming earnings report date?
ARS Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 8 days.
How were ARS Pharmaceuticals’s earnings last quarter?
ARS Pharmaceuticals released its earnings results on Aug 13, 2025. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.458 by -$0.002.
Is ARS Pharmaceuticals overvalued?
According to Wall Street analysts ARS Pharmaceuticals’s price is currently Undervalued.
Does ARS Pharmaceuticals pay dividends?
ARS Pharmaceuticals does not currently pay dividends.
What is ARS Pharmaceuticals’s EPS estimate?
ARS Pharmaceuticals’s EPS estimate is -0.46.
How many shares outstanding does ARS Pharmaceuticals have?
ARS Pharmaceuticals has 98,826,340 shares outstanding.
What happened to ARS Pharmaceuticals’s price movement after its last earnings report?
ARS Pharmaceuticals reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.458. Following the earnings report the stock price went down -5.042%.
Which hedge fund is a major shareholder of ARS Pharmaceuticals?
Currently, no hedge funds are holding shares in SPRY
ARS Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.00 (224.27% Upside)
$31.00 (224.27% Upside)
Blogger Sentiment
Bullish
SPRY Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 789.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 18.1%
Last 30 Days ▲ 18.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.27%
12-Months-Change
Fundamentals
Return on Equity
-23.56%
Trailing 12-Months
Asset Growth
41.23%
Trailing 12-Months
Company Description
ARS Pharmaceuticals
ARS Pharmaceuticals, Inc. (SPRY) is a biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company is known for its core product, neffy, a needle-free delivery system for epinephrine, aimed at treating severe allergic reactions and anaphylaxis. ARS Pharmaceuticals operates primarily in the healthcare sector, leveraging advanced delivery technologies to enhance patient experiences and improve outcomes in emergency situations.
SPRY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights significant growth in revenue and prescription volume for Neffy, along with expanded global presence and commercial coverage. However, high SG&A expenses and ongoing challenges with prior authorization requirements present some concerns. The positive aspects of the call, particularly the strong revenue growth and strategic global expansion, outweigh the lowlights.View all SPRY earnings summariesSPRY Stock 12 Month Forecast
Average Price Target
$31.00
▲(224.27% Upside)
Technical Analysis
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Pharming Group
―
Maze Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
60.68% Insiders
10.14% Mutual Funds
0.17% Other Institutional Investors
20.69% Public Companies and
Individual Investors